Molecular Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Obesity is a global metabolic health epidemic characterized by excessive lipid and fat accumulation, leading to severe conditions such as diabetes, cancer, cardiovascular disease. Immediate attention management of obesity-related risks are most warranted. The imbalance between absorption, rate, environmental genetic factors responsible for obesity. Treatment typically involves lifestyle modifications, pharmacotherapy, surgery. While changes crucial, effective treatment often necessitates medication preferred adjunct strategy. However, medications commonly used, oral show side effects due systemic exposure and, thus, may not effectively target the intended areas, drug loss. On other hand, transdermal administration drugs with microneedle (MN)-based technologies, painless delivery approach patient compliance, gaining interest an alternative obesity treatment, it directly targets adipose tissue via local delivery, minimizing system dose reduction. This Review addresses pathophysiology obesity, current strategies, challenges in using conventional formulations, importance use nano-based through MNs promising platform nanoparticle-based anti-obesity medications. potential combining stimuli-responsive non-responsive adjuvant therapies enhance efficacy outcomes explored. In addition, limitations future perspectives related addressed highlight transformative this technology management. hold promise precisely delivering while requiring lower dosages compared or injectable ultimately improving quality life individuals struggling its associated comorbidities.

Language: Английский